Treatment of ovarian cancer at the crossroads: 50 years after single-agent melphalan chemotherapy.

"Although the majority of patients with advanced ovarian cancer will die of the disease, optimism is justified in view of the improved results of surgery followed by cisplatin and carboplatin based chemotherapy."